Repligen (NASDAQ:RGEN) Releases FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Analysts Set New Price Targets

Several analysts recently weighed in on RGEN shares. Stifel Nicolaus raised their target price on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $230.00 to $200.00 and set an overweight rating for the company in a research note on Thursday. Finally, KeyCorp lifted their price target on Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of Moderate Buy and a consensus price target of $197.75.

Repligen Stock Performance

Shares of Repligen stock traded up $0.74 on Friday, hitting $167.05. The stock had a trading volume of 454,984 shares, compared to its average volume of 538,521. The stock has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a P/E/G ratio of 5.44 and a beta of 1.03. The company has a current ratio of 6.35, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The company’s 50 day moving average price is $180.81 and its 200 day moving average price is $173.90.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. Repligen’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 EPS. On average, research analysts anticipate that Repligen will post 1.46 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock valued at $5,039,532. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.